ScholarIQanswers from OpenAlex
Journal of Neurodevelopmental Disorders
JournalCitation impact & published research
Journal of Neurodevelopmental Disorders is a journal indexed in ScholarIQ from OpenAlex.
How many works does Journal of Neurodevelopmental Disorders have?
ScholarIQindexed works
Journal of Neurodevelopmental Disorders has 823 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Journal of Neurodevelopmental Disorders have?
ScholarIQcitation count
Journal of Neurodevelopmental Disorders has 30,581 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Journal of Neurodevelopmental Disorders?
ScholarIQh-index
Journal of Neurodevelopmental Disorders has an h-index of 87 in OpenAlex.
What is the article processing charge of Journal of Neurodevelopmental Disorders?
ScholarIQarticle processing charge
Journal of Neurodevelopmental Disorders lists an article processing charge of 2,690 USD in OpenAlex.
What is the OpenAlex record for Journal of Neurodevelopmental Disorders?
ScholarIQopenalex
The OpenAlex for Journal of Neurodevelopmental Disorders is on the source record.
What are the most-cited papers on Journal of Neurodevelopmental Disorders?
ScholarIQmost cited works
Association of oxytocin receptor (OXTR) gene variants with multiple phenotype domains of autism spectrum disorder
Jerry L. Campbell, Dibyadeep Datta, Shaine T. Jones, Evon Batey Lee, James S. Sutcliffe, Elizabeth A. D. Hammock, Pat Levitt
The benefit of directly comparing autism and schizophrenia for revealing mechanisms of social cognitive impairment
Noah J. Sasson, Amy E. Pinkham, Kimberly L. H. Carpenter, Ayşenil Belger
Four-year follow-up of a randomized controlled trial of choline for neurodevelopment in fetal alcohol spectrum disorder
Jeffrey R. Wozniak, Birgit A. Fink, Anita J. Fuglestad, Judith K. Eckerle, Christopher J. Boys, Kristin E. Sandness, Joshua P. Radke, Neely C. Miller, Christopher W. Lindgren, Ann M. Brearley, Steven H. Zeisel, Michael Georgieff
A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome
Helen Heussler, Jonathan Cohen, Natalie Silove, Nancy Tich, Marcel O. Bonn‐Miller, Wei Du, Carol O’Neill, Terri Sebree
Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium
Lauren Schwartz, Assumpta Caixàs, Anastasia Dimitropoulos, Elisabeth M. Dykens, Jessica Duis, Stewart Einfeld, Louise Gallagher, Anthony Holland, Lauren Rice, Elizabeth Roof, Parisa Salehi, Theresa V. Strong, Bonnie P. Taylor, Kate Woodcock